You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Merck
McKesson
Johnson and Johnson
Dow

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,365,500

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,365,500 protect, and when does it expire?

Patent 9,365,500 protects NUZYRA and is included in two NDAs.

This patent has eighty-two patent family members in twenty-three countries.

Summary for Patent: 9,365,500
Title:9-aminomethyl substituted minocycline compounds
Abstract: The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.
Inventor(s): Nelson; Mark L. (Norfolk, MA), Frechette; Roger (Reading, MA), Ismail; Mohamed Y. (Bedford, MA), Honeyman; Laura (Etobicoke, CA), Bowser; Todd (Charlton, MA), Bhatia; Beena (Mansfield, MA)
Assignee: PARATEK PHARMACEUTICALS, INC. (Boston, MA)
Application Number:14/318,031
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,365,500

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Paratek Pharms Inc NUZYRA omadacycline tosylate POWDER;INTRAVENOUS 209817-001 Oct 2, 2018 RX Yes Yes   Start Trial   Start Trial TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA   Start Trial
Paratek Pharms Inc NUZYRA omadacycline tosylate POWDER;INTRAVENOUS 209817-001 Oct 2, 2018 RX Yes Yes   Start Trial   Start Trial TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS   Start Trial
Paratek Pharms Inc NUZYRA omadacycline tosylate TABLET;ORAL 209816-001 Oct 2, 2018 RX Yes Yes   Start Trial   Start Trial TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA   Start Trial
Paratek Pharms Inc NUZYRA omadacycline tosylate TABLET;ORAL 209816-001 Oct 2, 2018 RX Yes Yes   Start Trial   Start Trial TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Colorcon
Baxter
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.